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Abstract
Four new protein-binding platinum(II) complexes, 10, 11, 21, 22, in which the dichloroplatinum moiety is
coordinated either to a carbon-substituted or a nitrogen-substituted ethylene diamino ligand, were prepared in
ten-step syntheses. According to pH-dependent stability studies with strictly related compounds, 11 and 22
exhibit acid-sensitive properties.
1. Introduction
Cisplatin and carboplatin are potent antineoplastic drugs which are widely used in anticancer chemotherapy.
They show their best results in the treatment of testicular and ovarian carcinoma and are also effective
against bladder tumours and tumours of the head and neck ]. However, both platinum complexes do not
accumulate in tumour tissues but are distributed rapidly throughout the body after parenteral administration
causing several side-effects such as nephrotoxicity, myelotoxicity, ototoxicity, nausea and vomiting ].
Hence, a major goal in anticancer chemotherapy is the development of drug delivery systems that transport
the drug to the tumour while largely sparing the healthy tissues of the body. In recent years, numerous
preclinical studies have shown that macromolecules such as synthetic polymers and serum proteins are taken
up by tumour tissue [2]. These polymers can accumulate in solid tumours due to an enhanced vascular
permeability of tumour blood vessels for circulating macromolecules combined with a lacking lymphatic
drainage system in the tumour.
Following this targeting strategy, we have developed several drug protein conjugates with organic anticancer
drugs, e.g. with anthracyclines or the alkylating agent chlorambucil [3-10]. In order to bind an active
cis-configurated platinum(II) complex to the surface of a macromolecular carrier, we set out to design
appropriate ligands that are able to form a complex with platinum(II) and are also able to bind to the
respective macromolecule as shown by the general structure in Figure 1:
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Figure 1: General structure ofplatinum(II) complexes capable ofbinding to macromolecules
In 1998, we reported on two platinum complexes in which the platinum moiety was bound to a spacer
through a stable aromatic or aliphatic ester bond and also contained a maleimide group that is able to react
specifically with thiolated macromolecules (see Figure 2) 11 ].
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Figure 2: Structures oftwo platinum complexes with maleimide groups and ester bonds
However, recent studies in our group have revealed that the chemical bond between the drug and the carrier
plays a crucial role for in vitro and in vivo activity. In our protein conjugates realised with anthracyclines or
alkylating agents, an acid-sensitive linker was used which acts as a predetermined breaking-point .releasing
the protein-bound drug either in the acidic environment of tumour tissue or in the acidic endosomal or
lysosomal compartments after cellular uptake ofthe conjugate by the tumour cell [3,10].
In subsequent biological studies, we were able to establish a correlation between the acid-sensitivity of the
chemical link and the antitumour activity of the conjugates: Drug protein conjugates in which the drug was
bound to the protein through an acid-sensitive carboxylic hydrazone bond showed high in vitro and in vivo
activity, whereas conjugates containing an ester or amide bond showed only marginal efficacy [4-7,9].
Carboxylic hydrazones have proven very useful as predetermined breaking-points because they are
sufficiently stable at pH 7.4 thus preventing the drug from being released in the blood stream- and they
also show acid-sensitive properties in a pH-range which is common in most tumour tissues and in relevant
organelles oftumour cells (pH range 4-6.5).
For these reasons, we prepared four maleimide containing platinum complexes with two different ligand
systems that incorporate a carboxylic hydrazone bond. The synthesis and characterisation of these complexes
are described in the following.
2. Results and Discussion
2.1. Platinum complexes with a N-(2-hydroxyethyl)-ethylene diamine ligand
The method of preparing the platinum(II) complexes 10 and 11, which contain the N-(2-hydroxyethyl)-
ethylene diamine ligand as the complexing moiety, is depicted in scheme 1. The starting compound 1 was
synthesised as described previously 11 ]. In afirst step, I was reacted with 4-formylbenzoyl chloride (2) and
4-acetylbenzoyl chloride (3), respectively. The resulting esters 4 and 5 could then be directly transformed
into the carboxylic hydrazones 6 and 7 by reaction with 3-maleimidobenzoylhydrazide trifluoroacetate which
was prepared in five steps according to the method ofBeyer et al. [12].
In the next step, the Boo-protecting groups (Boc= tert.-butoxycarbonyl) were removed. It proved best to use
pure trifluoroacetic acid in the absence of water, thus preventing a cleavage of the acid-sensitive hydrazone
bond. Isolation of $ and 9 was achieved by adding diethyl ether resulting in the precipitation of the amine
salts. In the last step, $ and 9 were treated with potassium tetrachloroplatinate(II) in a mixture ofDMF and
water until the solutions became bright yellow. Upon addition of excess water the platinum complexes 10
and 11 precipitated as pale yellow solids which were collected by filtration and dried in vacuo.
2.2. Platinum complexes with a 2,3-diaminopropionic acid ligand
Two further protein-binding platinum complexes containing the 2,3-diaminopropionic acid ligand were
synthesised as depicted in scheme 2. Initially, the starting material, D,L-2,3-diaminopropionic acid
hydrochloride, was Boc-protected by reaction with di-tert.-butyldicarbonate in a methanol/KOH/water
mixture. The resulting carboxylic acid 12 was then reacted with 4-hydroxybenzaldehyde (13) and 4-
hydroxyacetophenone (14), respectively, to form the esters 15 and 16.
The next reaction steps were performed in analogy to those described for the platinum complexes 10 and 11.
In the last step, the diamine trifluoroacetates were dissolved in DMF/water and neutralised with diluted
KOH. Subsequently, potassium tetrachloroplatinate(II)was added, and the solutions were stirred at room
temperature until the colour changed to yellow. Upon addition of water, 21 and 22 were obtained as pale
yellow solids.
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2.3. Charaeterisation
All synthesised compounds were characterised through 1H and 3C NMR spectroscopy and additionally by
elemental analysis (see Experimental Section). Furthermore, mass spectra of the four platinum complexes
were recorded.
NMR spectroscopy of the platinum complexes 10, 11, 21 and 22 revealed the characteristic singlet peaks of
the introduced maleimide group at 7.2 ppm for the protons ofthe double bond, the singlets at 8.5-8.6 ppm for
the aldehyde hydrazone protons of 10 and 21 as well as the singlets at 2.4 ppm for the methyl groups of 11
and 22. Additionally, all four complexes showed the typical signals of the maleimide group in the 3C NMR
spectra at 134-135 ppm for the carbon atoms ofthe double bond and at 169-170 ppm for the carbonyl group.
In the H NMR and 3C NMR spectra of the platinum complexes as well as of the carboxylic hydrazone
compounds (6-9 and 17-20) one set of signals was observed in DMSO-d6 indicating the presence of only one
stereoisomer. From a steric point of view, E-isomers are favoured, and we therefore tentatively propose that
this stereoisomer is present which is in accordance with studies on simple hydrazones 13].
The ESI mass spectra of the four complexes reveal the characteristic molecular peaks (M/+I) at 716, 730,
688 and 702 mass units for 10, 11, 21 and 22. In addition, the peaks M/+I-CI and M/+I-2C1 are distinctly
visible which correspond to the successive loss of the coordinatively bound chlorides. As an example, the
mass spectrum of21 in the range of600 to 700 mass units is shown in Figure 3.
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Figure 3" Mass spectrum ofthe platinum complex 21 in the range of600-700 mass units
3. pH-dependent hydrolysis studies
As mentioned above, the acid-sensitivity of the link between the drug and the carrier is an important
parameter for the antitumour activity of the conjugates. Hence, we wanted to perform pH-dependent
hydrolysis studies to determine the acid-sensitivity of our synthesised complexes. Unfortunately, the
platinum complexes 10, 11, 21 and 22 could not be used for this purpose due to their poor water-solubility.
The precursors of the platinum complexes are not suited either because the maleimide group is not
sufficiently stable in aqueous solutions over a period of several hours which is desired for performing
hydrolysis studies.
Therefore, we synthesised the model compounds 27 and 28 which are strictly related to 17 and 18, but
contain a non-hydrolysable succinic imide group instead of the maleimide group. The synthesis of the model
compounds is depicted in scheme 3.
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27 and 28 were not deprotected by acid cleavage because the resulting amine salts were difficult to analyse
by reverse phase HPLC using simple mixtures ofwater and an organic solvent. In contrast, 27 and 28 showed
def’mite elution profiles on a C18 reverse phase HPLC-column (eluent: acetonitrile/water 1"1; retention time
for 27 was 7.9 minutes and 8.9 minutes for 28).
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Figure 4: pH-dependent stability ofthe model compounds 27 and 28 at pH 7.4 and pH 4.0
over a range of 12 hours.
Hydrolysis studies were carried out as follows: Stock solutions of 27 and 28 (c 6.10
"5 mol/1) in acetonitrile
were prepared. 520 tl ofthe respective stock solution were diluted with 780 tl of buffer A (0.004 M sodium
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phosphate, 0.15 M sodium chloride, pH 7.4) or buffer B (0.004 M sodium phosphate, 0.15 M sodium
chloride, pH 4.0). Subsequently, 50 tl samples were analysed at 0, 3, 6, 9 and 12 h by HPLC (column:
Lichrosorb RP-18 (5tm), 1--30 cm, from Merck KGaA, Darmstadt, FRG) at k 280 nm using an
autosampler (determinations were carried out in triplicate). The rates of hydrolysis were measured by the
decrease of the peak areas of 27 and 28 and are depicted in Figure 4.
Both 27 and 28 do not hydrolyse at pH 7.4. At pH 4.0, however, 28 hydrolyses rapidly with a half-life of
approximately 3.5 hours. Interestingly, 27 does not exhibit pronounced acid-sensitive properties with less
than 10% being hydrolysed at pH 4.0 after 12 hours.
In summary, we have prepared four new protein-binding platinum complexes in which the dichloroplatinum
moiety is coordinated either to a carbon-substituted or a nitroAgen-substituted ethylene diamino ligand.
According to our pH-dependent stability studies with the strictly related model compounds 27 and 28, the
complexes containing an acetophenone benzoylhydrazone bond (11 and 22) exhibit acid-sensitive properties
in contrast to the two complexes 10 and 21 that contain a benzaldehyde benzoylhydrazone bond.
Preliminary experiments have shown that all four platinum complexes can be coupled to thiol-group bearing
macromolecules such as human serum albumin or polyethylene glycol-SH. Respective polymer conjugates
with 10, 11, 21 and 22 will be tested for antitumour activity in order to obtain structure-activity relationships
for the new platinum conjugates.
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4. Experimental Section
4.1. General
All chemicals were purchased from Aldrich, Fluka and Merck KGaA. Melting points: Btichi 530; H NMR
and 3C NMR: Bruker ARX 300 (internal standard: TMS); electron spray MS’ Finnigan-MAT 312; elemental
analysis: Perkin-Elmer elemental analyser 240; silica gel chromatography on silica gel 60 (0.063-0.100 ram)
from Merck KGaA; TLC: silica coated plates 60 F254 from Merck KGaA; organic solvents: p.a. grade and a
gift from BASF AG or purchased from Merck KGaA, FRG; KzPtCl4 was kindly provided by Asta Medica,
FRG.
4.2. Synthesis
4-formylbenzoyl chloride (2), 4-acetylbenzoyl chloride (3)
0.1 tool 4-carboxybenzaldehyde or 4-carboxyacetophenone was suspended in 300 ml toluene and treated with
0.3 mol thionyl chloride (36 g) under reflux (according to the method of Slotta and Kethur [14]) until the
suspension cleared. Excess thionyl chloride was then removed in vacuo, the remaining solution filtered and
evaporated to dryness. The yellow residue was crystallised from diethyl ether to yield
15.1 g (89.6 retool, 89.6%) 2 or 12.6 g (69.1 retool, 69.1%) 3 as yellow needles.
2:C8H5CIO2 (168.45 g/tool), m.p.: 54 C, calc.: C: 56.99%, H: 2.97%, CI: 21.04%, found:
C: 56.71%, H: 3.22%, Cl: 20.97%, H NMR (300 MHz, CDCI3): t5 10.0 (s, 1H, CHO), 8.1 (d, 2H, atom. H,
J23 J65 12.05 Hz), 7.9 (d, 2H, arom. H, 3J32 3J56 12.05 Hz), C NMR (75.4 MHz, CDCI): t5 189.9
(CHO), 163.4 (C_OCI), 135.9/132.6/127.0/126.6 (atom. C)
3: C9H7C[O (182.45 g/tool), m. 67 C, calc.: C: 59.19%, H: 3.84%, CI: 19.43%, found"
C: 59.06%, ISt: 3.76%, CI: 19.15%, lI NMR (300 MHz, CDCI): i 8.2 (_d, 2H, arom. H, aJ23 aJ6
8.66 Hz), 8.1 (d, 2H, atom. __H, 3J32 J56 8.66 Hz), 2.7 (s, 3H, CH__),C NMR (75.4 MHz, CDCI3):
6 197.0 (CH3CO), 167.9 (COCI), 141.8/136.5/131.5/128.6 (atom. C), 27.0 (CHa)
4-[3,6-bis-(tert.-butoxycarbonyi)-3,6.diazahexyloxycarbonyl]-benzaldehyde (4), 4-[3,6-bis-(tert.-butoxy-
carbonyl)-3,6-diazahexyloxycarbonyi]-acetophenone (5)
16.45 mmol and 16.45 mmol of either 2 or 3 were dissolved in 30 ml THF and 16.45 mmol pyridine (1.3 g)
added dropwise under vigorous stirring at room temperature. After 12 h pyridine hydrochloride was filtered
off and the filtrate evaporated to dryness in vacuo. The crude product was dissolved in a minimal amount of
ethyl acetate and purified by column chromatography (silica gel, ethyl acetate n-hexane 1:3) to yield
6.82 g (15.64 retool, 95.1%) of 4 or 6.79 g (15.09 retool, 91.7%) of 5.
4: Rf 0.44 (ethyl acetate n-hexane 1:2), CvH32N207 (436 g/,mol), m.p.: 84 C, calc.:
C: 60.55%, H: 7.34%, N: 6.42%, found: C" 60 79%, H’-7 24%, N" 6 46% IH NMR (300 MHz CDCh)"
3’ 10.1 (s, 1H, CHO), 8.2 (d, 2H, Har-3/Har-5, J32 J56 8.32 Hz), 7.9 (d, 2H, Har-2/Har-6, J,3 J5 8.32
Hz), 4.9 (d, 1H, N_H), 4.5 (s, 2H, OCH__z), 3.6/3.4/3.3 (3s, 6H, 3 NCH._2), 1.4 (s, 18H, 6 CH__3), C NMR
(75.4 MHz, CDCI3): t3 191.6 (CHO), 165.4 (Ar-COO), 155.5 (N_CO0), 139.3/134.9/130.3/129.5 (atom. C),
80.5 (C(CH3)3), 63.5 (O_CH_), 47.4/46.6/39.4 (3 NCH2), 28.3 (6 CH3)
5" Rf_ 0.43 (ethyl acetate n-hexane 1’2), C23H34NO7 (450 g/,mol), m.p.: 84 C, calc.:
1.3 O C" 6 3%, H" 7.56%, N" 6.22%, found: C: 61.08%, H: 7.31%, N: 6.08, H NMR (300 MHz, CDCI3):
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i 8.1 (dd, 2H, Ha,.-3/Ha..-5, 3J32 3j56 6.79 Hz, 4J35 1.89 Hz), 7.9 (dd, 2H, Ha,.-2/Ha,.-6, 3J23 3j65 6.79
Hz, 4J26 0.56 Hz), 4.8 (d, 1H, Nit), 4.4 (s, 2H, OCH,), 3.7/3.4/3.3 (3s, 6H, 3 NCI-t), 2.6 (s, 3H, COCH3)
1.3 (s, 18H, 6 CI-t3), 3C NMR (75.4 MHz, CDCI3): 5 197.5 (COCH3), 165.5 (Ar-COO), 155.5 (NCOO--),
140.3/133.7/130.0/128.2 (arom. C), 80.4 (C(CH3)3), 63.4 (OCH2), 47.5/46.6/39.4 (3 NCH_),’ 28.4
(6 CH3), 26.9 (COC_.H3)
4-[3,6-bis-(tert.-butoxycarbonyl)-3,6-diazahexyloxyearbonyll-benzaldehyde 3-maleimidobenzoyi-
hydrazone (6), 4-[3,6-bis-(tert.-butoxycarbonyl)-3,6-diazahexyloxycarbonyll-acetophenone
3-maleimidobenzoylhydrazone (7)
4.59 mmol 3-maleimidobenzoylhydrazide trifluoroacetate and 4.59 mmol of 4 or 5 were suspended in 40 ml
ethyl acetate and heated at 50 C until the suspension cleared. After stirring for 2 h at room temperature, the
solvent was removed in vacuo and the crude product purified by column chromatography (silica gel, ethyl
acetate n-hexane 1:1) to yield 1.5 g (2.31 retool, 50.3%) 6 or 1.3 g (1.96 retool, 42.7%) 7.
6" R-= 0.24 (ethyl acetate n-hexane 2:1), C33H39NsO9 (649 g/tool), m.p." 84 C, calc.:
C: 61.02%, H" 6.01%, N: 10.79%, found: C: 60.62%, H’ 6.20%, N’ 10.53%, ’H NMR (300 MHz, DMSOod6):
5 12.1 (s, 1H, C=NNH), 8.5 (s, 1H, N=CH), 8.1-7.9 (m, 4H, arom. H), 7.7 (m, 2H, arom. H), 7.6 (m, 2H,
atom H), 7.2 (s,2
HC=CH), 6.8 (bs, 1H, CHNH), 4.4 (m, 2H, OCH,), 3.5/3.3/3.1 (3s, 6H, 3 NCH), 1.3
(s, IH 6 CH__3), NMR (75.4 MHz, DMSO--d63" i 170.1 (OC-CH=CH-CO), 165.5 (At-COO), 162.8
(C=NNH-CO), 155.9 (C=N) 155.5 (NCOO), 147.1/139.0/135.2/132.3/130.9/130.1/129.5/127.5/127.1/126.6
(atom. C), 134.3 (HC=CH) 79.2/78.0 (2 C(CH3)3), 63.4 (OCH2), 47.0/45.8/38.5 (3 NCHz), 28.4 (6 CH3)
7. R 0 38 (ethyl acetate n-hexane 2"1), C34H4NsO9 (663 g/mol), m.p." 82 C, calc.:
C" 61.54%, "
6.18%, N: 10.56%, found: C: 60.78%, H: 6.08%, N" 10.04%, ’H NMR (300 MHz, DMSO-d6):
5 10.9 (s, 1H, C=NNH), 8.1-.7.5 (m, 8H, atom. H_H_), 7.2 (s, 2H, HC=CH), 6.8 (s, 1H, CH_NH), 4..4 (s, 2H,
OCH__2), 3.6/3.4/3.0 (3m, 6H, 3 NCFb), 2.4 (N=C-CH__3), 1.4 (s, 9H, 3 CH_H_3), 1.3 (s, 9H, 3 CH__3), ’3C NMR
(75.4 MHz, DMSO-d6): 6 169.8 (OC-CH=CH-CO), 165.2 (At-COO), 163.2 (C=NNH-CO), 155.6 (C=N),
154.6 (NC__OO), 142.3/131.6/130.0/129.2/128.8/126.5 (atom. C), 134.7 (HC=CH) 78.8 (C(CH3)3), 59.7
(OCH_), 46.7/45.5/38.1 (3 NCH_), 28.4 (6 _CH3), 28.0 (N=C-C_C_H3)
4-(3,6-diazahexyloxyearbonyi)-benzaldehyde 3-maleimidobenzoylhydrazone bis-trifluoroaeetate (8),
4-(3,6-diazahexyloxycarbonyl)-acetophenone 3-maleimidobenzoylhydrazone bis-trifluoroacetate (9)
1.54 mmol of 6 or 7 were treated with 2 ml trifluoroacetic acid for a few minutes at room temperature until a
clear viscous yellow solution was formed. The solution was triturated with 25 ml diethyl ether to produce
8 or 9 as precipitates, which were separated by filtration and washed twice with 25 ml diethyl ether.
The products were dried in vacuo to yield 0.93 g (1.37 retool, 89.2%) of 8 or 0.84 g (1.22 retool, 78.9%) of
9 as pale yellow powders.
8" C27H25NsO9F6 (677 g/tool), m.p." 92 C, calc." C: 47.86%, H" 3.69%, N" 10.34%, found: C: 46.25%,
H" 3.71%, N" 9.72%, H NMR (300 MHz, DMSO-d6): 6 12.2 (s, 1H, C=NNH), 9.3 (bs, 3H, NH__3+), 8.5
H, N=CH__), 8.2-7.7 (m, 8H, atom H), 7.6 (m, 2H, NH2+), 7.2 (s, 2H, H_C=CH), 4.5 (s, 2H, OCI-b),
6/3.4/3.2 (3m, 6H, 3 NCH_.2), 3C N1ViR (75 4 MHz, DM-O-d6): 6 169.7 (OC-CH=CH-CO), 165.1 (Ar-
COO), 162.4 (C=NNH-_CO), 158.8 (q, CF3COOH, J 30.2 Hz), 156.1 (C=N), 147.7/146.8/
138.9/133.9/131.9/130.1/129.1/127.0/126.7/126.2 (arom._C), 134.7 (HC=CH), 116.7 (q, CF3COOH, J
294.1 Hz), 64.2 (OCH_), 45.8/44.2/35.1 (3 NCH_)
9" C_8H_7NsO9F6 (691 g/tool), m.p." 125 C, calc.’ C’ 48.63%, H: 3.91%, N" 10.13%, found" C" 45.98%,
H" 3.82%, N" 9.71%, H NMR (300 MHz, DMSO-d6): 6 10.9 (s, IH, C=N-N__H), 9.4 (bs, 3H, NH__;+), 8.4-7.8
(m, 8H, atom. _H), 7.6 (m. 2H, NH_O,.z,+), 7.2 (s, 2H, HC=C__H), 4.6 (s, 2H, OCH,), 3.5/3.3/3.2 (3m, 6H,
3 NCH__2), 2.4 (N=C-CH__3), ’oC NMR (75.4 MHz, DMSO-d6)" i 169.8 (OC-CH=CH-CO), 165.2 (At-COO),
163.4 (C=NNH-CO), 158.9 (q, CF3COOH, 33.9 Hz), 155.6 (C=N) 142.7/140.3/132.8/131.7/129.9/
129.7/128.8/127.2/126.5 (atom. C_Q), 134.7 (HC=CH), 116.4 (q, CF3COOH, J 295.0 Hz), 60.6 (OCH2),
45.9/44.2/35.1 (3 NCH_), 27.2 (N=C-CH3)
N-[ 4-13-(3-maleimidobenzoyl)-2,3-diazaprop- 1 -en- -yl 1-benzoyioxyethyl]-ethylenediaminod ichloro-
platin(ll) (10), N-14-[ 4-(3-maleimidobenzoyl)-3,4-diazabut-2-en-2-yll-benzoyloxyethyil-ethylene-
diaminodichloroplatin(l 1) (11)
0.14 mmol K2PtCI4 were dissolved in 20 ml of DMF/water (80:20) and treated under stirring in the dark with
0.14 mmol of 8 or 9 dissolved in 10 ml DMF/water. The solution was stirred at room temperature until the
colour changed from red to yellow. Upon addition of 40 ml of water the platinum complexes 10 and 11
precipitated. The suspension was kept cool for 5 h to 4C to complete precipitation. The solids were filtered
off and washed twice with water, then twice with TI-IF, twice with diethyi ether and finally dried in vacuo to
yield 71.5 mg (0.1 retool, 71.4%) l0 or 80.2 mg (0.11 retool, 78.6%) 11.
10: C_3H.3NsOsPtCI_ (715 g/tool), m.p.: decomp. > 250 C, calc.: C: 38.60%, H: 3.22%, N: 9.79%,
Pt: 27.29%, CI: 9.92%, found: C: 37.28%, H: 3.58%, N: 9.13%, Pt: 26.79%, CI: 9.05%, H NMR (300 MHz,
DMSO-d6): 3 12.1 ,(s, IH, C=NNI-t), 8.6 (s, 1H, N=CH), 8.2-7.5 (m, 8H, atom. I-I), 7.2 (s, 2H, HC=CH),
4.6 (m, 2H, OCH), "C NMR (75.4 MHz, DMSO-d6): g 169.7 (O_C-CH=CH-__CO), 165.0 (Ar-_COO), 162.3
(C=NNH-CO), 1561 (C_.=N), 134.7 (HC__=C_.H), 61.5 (OC__2), 54.3/49.6/35.7 (3 NC_.H_,), ESI-MS (3.4 kV,
DMF/MeOH 7:1, re[. intensity)" m/z 716 (M/+l, 14), 680 (M--CI, 12), 643 (M/-2CI, 8)
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11: C24H_NsOPtCI_ (729 g/mol), m.p.: decomp. > 250 C, calc.: C: 39.51%, H: 3.43%, N: 9.60%,
Pt: 26.76%, CI: 9.73%, found: C: 38.24%, H: 3.67 %, N: 8.92/0, Pt: 25.89%, CI: 9.11%, H NMR (300 MHz,
DMSO-d6):=
10.9 (s, 1H, C=N-NH), 8.4-7.8. (m, 8H, arom. H), 7.2 (s, 2H, HC=CH), 2.4 (s, 3H,
N=C-CH_.3), ’CNMR (75.4 MHz, DMSO-d6)" i 169.8 (OC-CH=CH-CO), 165.2 (Ar-COO), 162.5
(C=NNH-CO), 155.7 (C=N), 134.7 (HC=H), 62.1 (OC__I-l+z)_, 56.8/50.2/371 (3 NCHz), ESI-MS (3.4 kV,
DMF/MeOH 7" l, rel. intensity)" m/z 730 (M+I, 18), 694 (M -CI, 48), 657 (M-2CI, 45)
N,N’-bis-(tert.-butoxycarbonyl)-D,L-2,3-diaminopropionic acid (12)
0.14 mol di-tert.-butyldicarbonate (30.96g) were added to a solution of 71.14 mmol D,L-2,3-
diaminopropionic acid hydrochloride (10 g) in a mixture of 100 ml methanol and 50 ml 4N KOH and the
reaction mixture was stirred for 12 h at room temperature. After removing methanol in vacuo, the aqueous
solution was acidified to pH with concentrated hydrochloric acid and extracted with ethyl acetate.
The organic layer was dried over sodium sulfate and concentrated in vacuo to yield 19 g (62.5 mmol, 87.9%)
of 12 as a white solid. C3H24N206 (304 g/mol), m.p.: 145 C, calc.: C: 51.32%, H: 7.89%, N: 9.21%, found"
C: 50.96%, H: 8.16%, N: 9.58%, HNMR (300 MHz, DMSO-d6): i 12.3 (bs, 1H, COOH), 6..8. (d, 1H,
CHNH), 6.7 (t, 1H, CH2NH) 3.9 (q, 1H, CH), 3.2 (t, 2H, CI-I), 1.4/1.3 (2s, 18H, 6 CH_.3), ’C NMR
(75.4 MHz, DMSO-d6): 173.1 (COOH), 156.5/156.1 (2 NCOO), 79.0/78.8 (2 C(CH3)3), 54.6 (CH), 42.0
(_.CH2), 29.0 (6 C__H3)
4-[N,N’-bis-(tert.-butoxycarbonyl)-l,L-2,3-diaminopropanoyloxy]-benzaldehyde (15), 4-[N,N’-bis-(tert.-
butoxyearbonyi)-t,L-2,3-diaminopropanoyioxy]-aeetophenone (16)
9.87 mmol 12, 9.0 mmol of 13 or 14 and 0.1 mmol N,N-dimethylaminopyridine (12 mg) were dissolved in
100 ml THF and 10 mmol N,N’-dicyclohexylcarbodiimide (2.1 g), dissolved in 20 ml THF, were then added
dropwise under stirring at 4 C. The solution was stirred for 2 h at 4 C, then for further 12 h at room
temperature and finally dicyclohexyl urea was filtered off. The filtrate was evaporated to dryness, dissolved
in 100 ml ethyl acetate and washed twice with 100 ml of a saturated NaHCO3 solution and then twice with
100 ml water. The organic layer was dried over sodium sulfate and concentrated to a volume of 50 ml.
n-hexane was added until a slight turbidity remained. In the cold at 4 C, colourless crystals formed yielding
2.97 g (7.28 mmol, 73.8%) of 15 or 1.80 g (4.26 mmol, 43.2%) of 16.
15: C9oH98N207 (408 g/mol), m.p.: 98 C, calc." C" 58 82%, H: 6.86%, N: 6.86%, found:
C" 58.5b% H: 7.15%, N: 6.87%, H NMR (300 MHz, DMSO-d6): "
10.0 (s, 1H, C_.HO), 8.0 (d, 2H, arom.
H, J 8.67 Hz), 7.3 (m, 33 2 arom. H/CHNH), 7.0 (t, 1H, CHNH), 4.3 (q, 1H, CH), 3.4 (m, 2H, CI-I), 14/1 (2s, 18H, 6 CH_.3), NMR (75.4 MHz, DMSO-d6): 5 1928 (CHO), 170.3 (CHCO), 156.5/156.2
(2 NCOO), 155.9/134.9/131.9/123.4 (arom. C), 79.7/79.1 (2 C(CH3)3), 55.2 (C_.H), 41.6 (C_.Hz), 29.0 (6 CH3)
16: CH30NgO7 (422 g/mol), m.p.: 110 C, calc.: C: 59.72%, H: 7.11%, N: 6.64%, found:
C: 60.40%, 7.22%, N: 6.79%, H NMR (300 MHz, DMSO-d6): i 8.0 (d, 2H, Har-2/Ha’6, 3Jz3 3J6s
8.67 Hz), 7.4 (d, 1H, CHNH), 7.3 (d, 2H, Har’3/Ha,.’5, 3J3 3j56 8.67 Hz), 7.0 (m, 1H, CHvNH), 4.3 (m, 1H,
CH), 3.4 (m, 2H, CH,), 2.’(s, 3H, COCH.O_3), 1.4/!.3 (2s, 18H, 6 CH_.3), 3C NMR (75.4 MH, ’MSO-d6): i
197.1 (COCH3), 169.7 (CHCO), 155.8/155.6 (2 NCOO), 154.3/134.8/130.1/122.1 (arom. C), 79.0/78.5 (2
C(CH3)3), 54.5 (CH), 41.0 (CH2), 28.3/28.2 (6 CH3), 26.9 (COCH3)
4-[N,N’-bis-(tert.-butoxyearbonyl).D,L-2,3.diaminopropanoyioxyl-benzaldehyde 3-maleimido-
benzoylhydrazone (17)’
3.68 mmol 3-maleimidobenzoylhydrazide trifluoroacetate and 3.68 mmol 15 were suspended in 30 ml ethyl
acetate and heated at 50C until the suspension cleared. The product precipitated in the heat, was filtered off
and crystallised from methanol to yield 1.88 g (3.03 mmol, 82.3%) 17..
C3H35NO9 (621 g/mol), m.p.: 224 C, calc.: C: 59.90%, H: 5.64%, N: 11.27%, found:
C: 60.58%, H: 5.34%, N: 11.51%, H NMR (300 MHz, DMSO-d6): 5 =12.0 (s, 1H, C=NN_H), 8.5 (s, 1H,
N=CH), 8.0-7.4 (m, 8H, arom. H), 7.3 (d, 1H, CHNH), 7.2 (s, 2H, HC=C_H), 7.0 (t, 1H, CHiN_H), 4.3 (q, H,
CH), 3.5 (m, 2H, CH), 1.4/1.3 (2s, 18H, 6 CH_H_3), 3-NMR (75.4 MHz, DMSO-d6): i-- 169.7 (OC-CH=CH
_CO), 169.6 (CHCO), 162.2 (C=NNH-CO), 155.5/155.3 (2 N_COO), 151.6 (C=N) 147.1/
134.1/131.9/131.8/130.0/129.0/128.2/126.6/126.1/122.1 (arom._C), 134.7 (HC=_CH), 78.7/78.2 (2 C_.(CH3)3),
54.2 (CH), 40.7 (CH.,), 28.1/28.0 (6 _.CH3)
4-[N,N’-bis-(tert.-butoxycarbonyl)-I),L-2,3.diaminopropanoyloxy]-aeetophenone 3-maleimido-
benzoyihydrazone (18)
5.92 mmol 3-maleimidobenzoylhydrazide trifluoroacetate and 5.92 mmol 16 were suspended in 30 ml ethyl
acetate and heated at 50C until the suspension cleared. The mixture was then concentrated to a minimal
volume and separated by column chromatography (silica gel, ethyl acetate / n-hexane 3:2) to yield 2.22g
(3.50 mmol, 59.1%) 18 as a colourless powder.
Rf 0.35 (ethyl acetate / n-hexane 2:1), C32H37NsO9 (63,5 g/mo0, m.p" 93 C, calc." C: 60.47%, H: 5.83%,
o o N" 11.02’, found: C: 60.72, H: 5.45%, N: 11.17%, ’H NMR (300 MHz, DMSO-d6): 5 10.9 (s, 1H,
C=NNH), 8.0-7.5 (m, 6H, atom. H), 7.4 (d, 1H, CHNH), 7.2 (m, 4H, arom. _.H/_.HC=C_.H), 7.1 (t, 1H, CH2NH),
4.3 (m, 1H, CH), 3.4 (m, 2H, CH._2,), 2.4 (s, 3H, N=C-CH_.3), 1.4 (s, 9H, 3 CH__3), 1.3 (s, 9H, 3 CH__3), 3CNI
(75.4 MHz, DMSO-d6): 5 170.3 (OC-CH=CH-CO), 169.7 (CHCO), 163.1 (C=NNH-CO), 155.6/155.3
(NCOO), 151.4 (C=N), 135.7/131.7/129.7/128.9/127.6/127.0/12.6.3/121.5 (atom. C), 134.7 (HC=CH),
78.4/78.2 (C(CH3)3), 54.2 (C_.H), 40.8 (CH2), 28.1 (6 CH3), 28.0 (N=C-C_.H3)
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4-(D,L-2,3-diaminopropanoyloxy)-benzaldehyde 3-maleimidobenzoylhydrazone bis-trifluoroacetate
(19), 4-(D,L-2,3-diaminopropanoyloxy)-acetophenone 3-maleimidobenzoyihydrazone bis-
trifluoroacetat (20)
1.61 mmol 17 or 18 were treated at room temperature with 2 ml trifluoroacetic acid for a few minutes until a
clear viscous yellow solution was formed. Under vigorous stirring, 25 ml diethyl ether were added resulting
in the precipitation of 19 or 20, which were separated by filtration and washed twice with 25 ml diethyl ether.
The products were dried in vacuo to yield 0.88 g (1.36 mmol, 84.5%) 19 or 0.84 g (1.27 mmol, 78.7%) 20.
19:CsH21NsO9F6 (649 g/mol), m.p.: 66 C, calc.: C: 46.22%, H: 3.24%, N: 10.79%, found: C: 44.62%,
H: 3.2"1%, N: 9.79%, H NMR (300 MHz, DMSO-d6): 5 12.0.(s, 1H C=NNH), 8.7 (bs, 6H, 2 N.H.H+), 8.5
(s, 1H, N=CH), 8.0-7.3 (m, 8H, arom. H), 7.2 (s, 2H, HC=CH), 4.6 (t, 1H, CH), 3.5 (m, 2H, CH.O_2), ’C NMR
(75.4 MHz, DMSO-d6): 170.7 (OC__-CH=CH-CO), 166.5 (CHCO), 163.2 (C=NNH-CO), 159.5
(q, CF3COOH, J 32.7 Hz), 151.7 (C=N), 134.9 (HC=CH), 147.9-122.9 (arom. C), 117.7 (q, CF3COOH, J
297.2 Hz), 51.2 (CH), 39.1 (CH2)
20:C26H23NsO9F6 (66,3 g/mol), m.p.’ 82 C, calc.: C: 47.06%, H: 3.47%, N: 10.56%, found: C: 45.89%,
H" 3.39%, N: 9.88%, ’H NMR (300 MHz, DMSO-d6)’ 5 11.0 (s, 1H, C=NNH), 9.0 (bs, 6H, 2 NH__3+),
8.0-7.3 (m, 8H, arom. H), 7.2 (s, 2H, HC=CH), 4.7 (m, 1H, CH), 3.6 (m, 2H, CI-I), 2.4 (s, 3H, N=C-CH_.3),
13C NMR (75.4 MHz, DMSO-d6): i 169.8 (OC-CH=CH-CO), 165.6 (CHCO), 163.4 (C=NNH-CO), 159.5
(q, CF3COOH, J 33.1 Hz), 150.7 (_.C=N), 134.8 (HC_.=CH), 136.5-121.5 (arom. C), 117.7 (q, CF3COOH, J
296.9 Hz), 50.4 (CH), 40.2 (CH2), 26.7 (N=C-CH3)
(R,S)- -! 4-13-(3-maleimidobenzoyl)-2,3-diazaprop- 1-en- 1-yi]-phenoxycarbonyll-ethylenediamino-
dichloroplatin(ll) (21), (R,S)-l-14-14-(3-maleimidobenzoyi)-3,4-diazabut-2-en-2-yli-phenoxyearbonyll-
ethylenediaminodichioroplatin(ll) (22)
0.15 mmol 19 or 20 were dissolved in 10 ml DMF/water (80:20) and neutralised with 1.5 ml 0.1N KOH.
These solutions were added to 0.15 mmol K2PtCI4, dissolved in 20 ml DMF/water (80:20), under stirring in
the dark. Stirring was continued until the colour changed from red to yellow. Upon addition of 40 ml of water
the platinum complexes 21 and 22 precipitated. The suspension was cooled for 5h to 4C to complete the
precipitation. The precipitate was filtered off and washed twice with water, then twice with THF, twice with
diethyl ether and finally dried in vacuo to yield 88.8 mg (0.13 mmol, 86.7%) 21 or 84.1 mg (0.12 mmol,
80.0%) 22.
21:C2HI9NsOPtCI2 (687 g/mol), m.p.: decomp. > 250 C, talc.: C: 36.68%, H: 2.76%, N: 10.19%,
Pt: 28.40%, CI: 10.32%, found: C: 35.06%, H: 2.84%, N: 9.77%, Pt: 27.12%, Cl: 9.43%, H NMR
(300 MHz, DMSO-d): 5 12.1 (s, 1H, C=N-NH), 8.5 (s, 1H, N=CH), 8.0-7.5 (m, 8H, arom.,H_), 7.3 (d, 2H,
CHNH__), 7.2 (s, 2H, HC=CH__), 6.8 (m, 2H, CHNH.), 4.1 (m, 1H, CH), 3.1 (m, 2H, CH._2), C NMR (75.4
MHz, DMSO-d): 5 169.7 (OC_-CH=CH-__CO), 166.1 (CHC_.O), 162.2 (C=NNH-C_.O), 148.4 (C_.=N), 134.7
(HC=C+H), 60.3 (_CH), 48.5 (_CH2), ESI-MS (3.8 kV, DMF/MeOH 7:1, rel. intensity): m/z 688 (M/+I, 54),
652 (M -CI, 59), 615 (M-2Cl, 20)
22: C22H2NOPtCIz (701 g/mol), m.p.: decomp. > 250 C, calc.: C: 37.66%, H: 3.00%, N: 9.99%,
Pt: 27.83%, CI: 10.11%, found: C: 37.06%, H: 3.57%, N: 10.53%, Pt: 26.88%, CI: 9.42%, H NMR
(300 MHz, DMSO-d6): i 10.9 (s, 1H, C=NNH), 8.1-7.5 (m, 8H, arom. H), 7.2 (s, 2H, HC=CH), 2.4 (s, 3H,
N=C-CH__3), t3C NMR (75.4 MHz, DMSO-d6): 169.7 (OC-CH=CH-CO), 166.7 (CHCO), 163.2 (C=NNH
CO), 151.8 (C=N), 134.7 (HCCH), 60.3 (CH)+, 48.5 (CH2), 26.7 (N=C-CH3), ESI-MS (3.4 kV, DMF/MeOH
7:1, tel. intensity): m/z 702 (M +1, 45), 665 (M -CI, 25), 629 (M*-2CI, 13)
3-succinimidobenzoic acid (23)
0.36 tool 3-aminobenzoic acid (50 g) were dissolved in 550 ml THF by heating at 50 C and 0.43 tool
succinic anhydride (43 g) were added in ten portions. After stirring for 2 h at room temperature the resulting
precipitate was filtered off and washed with a small amount of THF. The crude product was then suspended
in 100 ml THF and treated with 1.44 mol acetic anhydride (147 g) and 0.36 mol sodium acetate (30 g) under
reflux until an almost clear solution was formed. Excess acetic anhydride was hydrolysed by adding water
and heating the solution under reflux for h. After cooling to room temperature, concentrated hydrochloric
acid was added until 23 began to precipitate. The suspension was cooled to 4 C for 5 h. Then the precipitate
was filtered off, washed with water and dried in vacuo to yield 71 g (0.32 mol, 88.8%) 23.
o O CH9NO4 (2,19 g/mol), m.p." 225 C, calc.: C" 60.27%, H: 4.11%, N: 6.39%, found: C: 60.41 , H: 4.10A,
N: 6.56%, ’H NMR (300 MHz, DMSO3d6): 5 13.1 (s, 1H, COO__H), 7.9 (m, 2H, arom. H), 7.5
(m, 2H, atom. H), 2.7 (s, 4H, H._.zC-CH__2), C NMR (75.4 MHz, DMSO-d6): 5 176.8 (O_C-CH2CH2-C_.O),
166.5 (COOH), 132.9/131.4/131.3/129.1/128.8/128.0 (atom. _.C), 28.4 (H:C-CH2)
3-succinimidobenzoyi chloride (24)
0.21 tool 23 (46 g) were suspended in 200 ml of toluene and treated with 0.63 tool thionyl chloride (75 g)
under reflux until a solution was formed. Excess thionyl chloride was removed by distillation and toluene
was subsequently evaporated in vacuo. The brownish residue was crystallised from acetone and washed with
small amounts of n-hexane. The product was dried in vacuo to yield 38.9 g (0.16 tool, 76.2%) of 24.
CIHsNO3CI (237.45 g/tool), m.p.: 100 C, calc.: C: 55.59%, H: 3.37%, N: 5.90%, Cl: 14.93%, found:
C: 55.90%, H: 3.19%, N: 5.73%, CI: 14.62%, H NMR (300 MHz, DMSO-d6): 5 7.9 (m, 2H, atom. H),
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7.5 (m, 2H, arom. H), 2.8 (s, 4H, H,C-CH_H_2), 3C NMR (75.4 MHz, DMSO-d6): 8 176.4 (OC-CH2CH2-CO),
166.0 (C_OCI), 132.5/131.7/131.0/129.6/128.4/127.5 (atom. _G.C), 28.5 (H2C-CH2)
l-(3-succinimidobenzoyi)-2-(tert.-butoxycarbonyl)-hydrazine (25)
42.1 mmol 24 (10 g) and 42.1 mmol tert.-butylcarbazate (5.56 g) were dissolved in 160 ml THF and treated
under vigorous stirring with 42.1 mmol triethylamine (5.85 ml). After 10 minutes the reaction was complete.
The precipitated triethylammonium chloride was filtered off and the filtrate evaporated to dryness in vacuo,
dissolved in ethyl acetate and washed twice with 100 ml 0.5 N hydrochloric acid and then twice with 100 ml
saturated NaCI solution. The organic phase was concentrated and cooled to 0C to yield 11.95 g (35.9 retool,
85.3%) of 25 as a colourless powder.
C16HIgN305 (333 g/mo, l), m.p." 184 C, calc." C: 57.66%, H" 571%, N" 12.61%, found" C: 58.20%,
H: 5.94%, N: 12.66%, ’H NMR (300 MHz, DMSOod6)" i 10.3/8.9 (2s, 2H, 2 NH), 7.9-7.4 (m, 4H, atom.
H), 2.8 (s, 4H, I-t,C-CI-t), 1.4 (s, 9H, 3 CH_.3), 3C NMR (75.4 MHz, DMSO-d6): 5 176.7 (OC-CHzCH2-
CO), 165.1 (Ar-CONH), 155.3 (NCOO), 133.2/132.9/130.3/128.9/126.5/126.4 (arom. C), 79.2 (C(CH3)3),
28.4 (3 _.CH3), 28.0 (H,C-CH2)
3-succinimidobenzoyihydrazide trifluoroacetate (26)
15.0 mmol 25 (5 g) were treated with 20 ml trifluoroacetic acid at room temperature, until a solution was
formed. 100 ml diethyl ether were added under vigorous stirring resulting in the precipitation of 26, which
was separated by filtration and washed twice with 25 ml diethyl ether. The product was dried in vacuo to
yield 4.16 g (11.99 retool, 79.9%) of 26 as a colourless powder.
CI3H2N3OsF3 (347 g/m91 ), m.p.: 89 C, calc.: C: 44.96%, H: 3.46%, N: 12.10%, found: C: 44.12%,
H: 3.40%, N: 11.81%, ’H NMR,300 MHz, DMSO-d6): 9.3 (bs, 4H, NHfNH3+), 7.9-7.6 (m, 4H,
atom. __H), 2.8 (s, 4H, H__2C-CH__2), C NMR (75.4 MHz, DMSO-d6): 177.0 (OC-CH2CH2-CO), 165.4
(Ar-CONH), 162.1 (q, CF3C_.OOH, J 33.7 Hz), 136.7/134.9/134.7/132.8/130.4/130.0 (atom. C), 121.9 (q,
CF3COOH, J 295.4 Hz), 28.7 (H2C__-CH2)
4-[N,N’-bis-(tert.-butoxycarbonyi)-D,L-2,3-diaminopropanoyloxyl-benzaidehyde 3-succinimido-
benzoylhydrazone (27)
5.76 mmol 26 (2 g) and 5.76 mmol 15 (2.35 g) were suspended in 50 ml ethyl acetate and heated at 50 C
until precipitation occurred. The precipitate was filtered off and crystallised from methanol o yield
2.29 g (3.68 retool, 63.9%) 27.
C31H37NsO9 ,(623 g/too0, m.p.: 184 C, calc.: C" 59.71%, H" 5.94%, N: 11.24%, found: C 59.51%, H: 6.13%,
N: 11.03%, ’H NMR (300 MHz, DMSO-d6): 8 11.9 (s, IH, C=NNH), 8.5 (s, 1H, N=CH), 8.0-7.2 (m, 8H,
arom. H), 7.4 (d, 1H, CHNH), 7.0 (t, 1H, CH2NH_.), 4.3 (m, 1H, CH__), 3.4 (m, 2H, CH,), 2.8 (s, 4H, H__2C-CH__2),
1.4/1.3 (2s, 18H, 6 CH__3), ’oC NMR (75.4 MHz, DMSO-d6): 3 177.7 (OC-CH2CH2-CO), 170.5 (CHCO),
163.1 (C=NNH-_CO), 156.5/156.2 (2 NC_OO), 152.6 (C=N), 148.1/135.0/134.0/133.0/131.3/129.9/129.1/
127.9/127.6/123.0 (atom. C), 79.6/79.1 (2 C(CH3)3), 55.1 (C_H), 41.7 (CH2), 28.4 (H,C-CH2), 28.0 (6 CH3)
4-[N,N’-bis-(tert.-butoxycarbonyl)-O,L-2,3-diaminopropanoyloxyl-acetophenone 3-succinimido-
benzoylhydrazone (28)
5.76 mmol 26 (2 g) and 5.76 mmol 16 (2.43 g) were dissolved in 50 ml THF and stirred for 2 h at room
temperature. THF was then evaporated in vacuo and the residue dissolved in a minimal amount of ethyl
acetate and purified by column chromatography (silica gel, ethyl acetate n-hexane 1:1) to yield 1.20 g
(1.89 retool, 32.8%) 28.
Rf 0.23 (ethyl acetate n-hexane 1’1), C32H39NsO9 (637 g/mol), m.p." 168 C, calc.: C: 60.28%, H" 6.12%,
N" 10.99%, found" C" 60.40%, H" 6.15 %, N: 10.70%, H NMR (300 MHz, DMSO-d6): 10.9 (s, 1H,
C=NNH), 7.9-7.0 (m, 8H, atom. H), 7.4 (d, 1H, CHNH), 6.9 (t, 1H, CH2N__H), 4.3 (’3 1H, CH), 3.4 (m, 2H,
CH,), 2.8 (s, 4H, H__2C-CH__2), 2.3 (s, 3H, N=C-CH__3), 1.4/1.3 (2s, 18H, 6 CH__3), C NMR (75.4 MHz,
DMSO-d6): 177.0 (OC-CH2CH2-CO), 169.9 (CHCO), 163.3 (C=NNH-CO), 155.8/155.6 (2 NCOO),
151.6 (C=N), 135.9/135.0/133.1/132.9/130.3/128.9/127.8/127.1/121.7 (atom. C), 78.9/78.4 (2 C(CH3)3), 54.4
(CH), 41.1 (CH_), 28.7 (H,C-CH2), 28.3 (6 CH3), 26.6 (N=C-CH3)
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